Who founded Komo Biosciences?

Komo Biosciences was founded by Jennifer Manning.

Who are Komo Biosciences's investors?

Komo Biosciences's investors include Genesis BioCapital, Eshelman Ventures, LLC, Modi Ventures, GENERAL INCEPTION, LDV Partners.

Komo Biosciences

5 known investors

KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.

Biotech Deep Tech

Founders & leadership

Jennifer ManningFounder & CEO

Thomas PageActing CTO

Matt FarabaughActing CFO

Jesse B. OwensinActing CSA

Board

Ray TabibiazarChairman of the Board

Investors · 5

Genesis BioCapital✓ verifiedChattanooga

Eshelman Ventures, LLCWilmingtonvia Fred Eshelman · inferred

Modi VenturesHouston

GENERAL INCEPTIONreportedPalo Alto

LDV PartnersreportedPalo Alto

Competitors · 3

by search overlap

Precision BioSciences5 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

IQVIA4 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Curi Bio3 shared keywordsCuri Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.

Companies competing with Komo Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Revolutionary Gene Editing Startup Komo Biosciences Emerges with Breakthrough Integrase Technology from University of Hawaii | BioBuzzbiobuzz.io · Jul 2024

Frequently asked questions

What does Komo Biosciences do?: KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.
Who founded Komo Biosciences?: Komo Biosciences was founded by Jennifer Manning.
Who are Komo Biosciences's investors?: Komo Biosciences's investors include Genesis BioCapital, Eshelman Ventures, LLC, Modi Ventures, GENERAL INCEPTION, LDV Partners.